Optometry in Practice (OiP), the College's quarterly CPD journal, covers the latest research, analysis and opinion from your profession, and provides up to 4 CPD points.
A review of the modern classifications of AMD and available treatments.
Introduction
Age-related macular degeneration (ARMD) is the commonest cause of visual impairment leading to blind registration among older adults in the western world. Following recently published trials, ophthalmologists around the world now have the knowledge and the drugs to improve visual outcomes and to provide much-needed hope to patients with wet macular degeneration. Further, many research trials are currently under way with more funding to find an even more suitable and effective treatment modality for macular degeneration.
Sign in to continue
Sign in to view the article
Not a member? Start enjoying the benefits of College membership today. Take a look at what the College can offer you and view our membership categories and rates.
Adrian O’Dowd explores a new treatment for late-stage dry AMD being considered for approved use in the UK that could raise hopes of delaying the irreversible sight loss caused by the disease.